These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9573653)

  • 41. Imipenem but not meropenem induces convulsions in DBA/2 mice, unrelated to cerebrospinal fluid concentrations.
    Dupuis A; Pariat C; Courtois P; Couet W; Bouquet S
    Fundam Clin Pharmacol; 2000; 14(2):163-5. PubMed ID: 10796065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Newer carbapenems for urinary tract infections.
    Matsumoto T; Muratani T
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S35-8. PubMed ID: 15364304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune response in patients with intra-abdominal infections treated with carbapenems.
    Brismar B; Eklund AE; Nord CE
    Int J Clin Pharmacol Res; 1994; 14(3):111-4. PubMed ID: 7883388
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group.
    Hamacher J; Vogel F; Lichey J; Kohl FV; Diwok K; Wendel H; Lode H
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():121-33. PubMed ID: 8543488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative convulsant potencies of two carbapenem derivatives in C57 and DBA/2 mice.
    de Sarro A; Imperatore C; Mastroeni P; de Sarro G
    J Pharm Pharmacol; 1995 Apr; 47(4):292-6. PubMed ID: 7791026
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
    Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
    Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and economic evaluation of subsequent infection following intravenous ciprofloxacin or imipenem therapy in hospitalized patients with severe pneumonia.
    Caldwell JW; Singh S; Johnson RH
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():129-34. PubMed ID: 10225583
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses.
    Orsini JA; Moate PJ; Boston RC; Norman T; Engiles J; Benson CE; Poppenga R
    J Vet Pharmacol Ther; 2005 Aug; 28(4):355-61. PubMed ID: 16050815
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
    Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
    Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
    Jones RN; Mendes C; Turner PJ; Masterton R
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carbapenems in the USA: focus on doripenem.
    Lister PD
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacoeconomics of meropenem versus imipenem/cilastatin].
    Marquina MC; Giráldez J; Idoate A
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():45-50. PubMed ID: 9410069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients.
    Moon YS; Chung KC; Gill MA
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S249-55. PubMed ID: 9126700
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule.
    Watt B; Edwards JR; Rayner A; Grindey AJ; Harris G
    Tuber Lung Dis; 1992 Jun; 73(3):134-6. PubMed ID: 1421344
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.
    Edwards SJ; Emmas CE; Campbell HE
    Curr Med Res Opin; 2005 May; 21(5):785-94. PubMed ID: 15969878
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness study of imipenem/cilastatin versus meropenem in intra-abdominal infections.
    Attanasio E; Russo P; Carunchio G; Basoli A; Caprino L
    Dig Surg; 2000; 17(2):164-72. PubMed ID: 10781982
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
    Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V
    J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients.
    Shah PM; Heller A; Fuhr HG; Walther F; Halir S; Schaumann R; Böhme A; Jung B; Köhler A; Lips-Schulte C; Stille W
    Infection; 1996; 24(6):480-4. PubMed ID: 9007599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium].
    Daimon Y
    Jpn J Antibiot; 1990 Nov; 43(11):1948-55. PubMed ID: 2287059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
    Novelli A; Adembri C; Livi P; Fallani S; Mazzei T; De Gaudio AR
    Clin Pharmacokinet; 2005; 44(5):539-49. PubMed ID: 15871639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.